November 16, 2011 — The American Society of Echocardiography (ASE) issued a response voicing concerns over the implications of a study published this week in the Journal of the American Medical Association (JAMA).

Wireless Cardiac Stimulation System (WiCS)

November 15, 2011 – The new full iterative technology (FIT) now available on the BrightView XCT uses advanced algorithms for the truest picture possible. New clinical cases show that concurrent imaging allows for shorter exams and smarter assessments.  

Radsource is an innovative, highly specialized teleradiology practice that provides musculoskeletal and neurological magnetic resonance imaging (MRI) interpretation services. Headquartered in Brentwood, Tenn., Radsource is staffed by a team of 20 sub-specialized radiologists who read 140,000 studies annually for customers spanning more than 50 locations across the United States.

Radsource radiologists read and interpret studies in a highly collaborative environment enabled by Intelerad’s IntelePACS system.

All Radsource physicians use the IntelePACS integrated worklist and viewer. The intuitive, shared Intelerad Reporting Worklist optimally distributes the workload while providing the ability to collaborate on cases – thus leveraging all the expertise within the group to effect the highest quality interpretations.

“The ability to interact clinically while viewing the images is really an important part of building that client relationship,” says Mark Awh, M.D., Radsource president. High levels of interaction among the radiologists, as well as with their referring physicians, are key contributors to the unparalleled quality and service for which Radsource is known. The end result is greatly enhanced patient care.
 

November 14, 2011 — GE Healthcare announced it recently submitted to the U.S. Food and Drug Administration (FDA) the first module of its premarket approval application (PMA) for GE Breast Tomosynthesis. The module is an option of the Senographe Essential system.

November 14, 2011 - U-Systems announced the U.S. Food & Drug Administration (FDA) has cleared the premarket approval (PMA) application for breast cancer screening indication for use for the somo•v Automated Breast Ultrasound (ABUS) system. The system is currently FDA-cleared for diagnostic use as an adjunct to mammography. 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now